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Atopic dermatitis (AD) is a recurrent, chronic eczematous skin condition with a rapidly rising 
global frequency.1 Massive advances in cutaneous immunology have provided thorough 
documentation on the pathophysiology of AD in the last few decades. These innovations 
revealed a large number of candidate therapeutic targets, and it is now beginning to bear fruit 
with the advent of various biologics and small molecules. In particular, dupilumab, a fully 
humanized anti-IL4Rα monoclonal antibody, has demonstrated to have remarkable efficacy 
and relative safety in the aspects of adverse events in both clinical trials and real-world 
settings.2-9 Nonetheless, the cost of dupilumab is quite exorbitant, particularly in Korea, 
and only a small percentage of patients can be covered by the national health insurance 
program due to stringent requirements. In spite of the situations where dupilumab can be 
used, it is often the case that the use of dupilumab is given up for economic reasons. Also, 
adverse events, including dupilumab-induced facial erythema10 and dupilumab-induced 
ocular surface diseases,11 occasionally limit the consistent injection of dupilumab. Even if 
the efficacy is good and well tolerated, there may be cases where it is required to increase the 
interval of dupilumab injections.
In the current issue of the Allergy, Asthma & Immunology Research, Lee et al.12 assessed the 
efficacy of dupilumab and predictive biomarkers for favorable responses. In total, 57 
moderate-to-severe AD adult patients who received dupilumab every 4 weeks for 16 weeks 
were analyzed. In this article, the Eczema Area and Severity Index (EASI) at baseline was 
compared with that at week 16. Also, the proportion of patients with a 50% or 75% decrease 
in EASI at week 16 was evaluated (EASI-50 or EASI-75). They showed that monthly dupilumab 
therapy significantly decreased EASI (27.8 ± 11.1 at baseline vs 8.7 ± 7.8 at week 16; P < 0.001); 
EASI-50, EASI-75, and EASI-90 responses at week 16 were observed in 48 (84.2%), 27 (47.4%), 
and 9 (15.8%) patients, respectively. Considering the efficacy results from 2 phase III clinical 
trials (SOLO 1 and SOLO 2) whose EASI-50, EASI-75, and EASI-90 responses at week 16 were 
69%, 51%, and 36%, respectively, for SOLO 113 as well as 65%, 44%, and 30% for SOLO 2,13 
it seems that the efficacy of the monthly dupilumab use could be comparable to that of the 
2-week interval use. However, these results may have been attributed to a relatively small 
number of subjects and its study design of retrospective analysis, so these data should be 
interpreted with caution.
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Does Monthly Dupilumab Therapy 
Maintain its Clinical Efficacy in 
Moderate-to-Severe Atopic Dermatitis?
► See the article “Real Clinical Practice Data of Monthly Dupilumab Therapy in Adult Patients With 
Moderate-to-Severe Atopic Dermatitis: Clinical Efficacy and Predictive Markers for a Favorable 
Clinical Response” in volume 13 on page 733.
Recently, as new therapeutics which reflect the pathophysiology of AD have emerged, much 
research focuses on changes in histological and/or serological biomarkers that occur along 
with clinical improvement when biologics and/or small molecules are used. In particular, a 
considerable number of studies on dupilumab biomarkers were published in 2020. Katoh et 
al.14 suggested the thymus and activation-regulated chemokine (TARC) and immunoglobulin 
E (IgE) as serum biomarkers based on the clinical response with Japanese subgroup phase III 
clinical trial data. Also, Kato et al.15 analyzed 54 Japanese adult AD patients and reported that 
higher serum lactate dehydrogenase (LDH) levels might be associated with poor response 
to dupilumab. Ariëns et al.16 analyzed 35 adults AD patients from BioDay registry, and 
demonstrated that TARC, pulmonary and activation-regulated chemokine (PARC), Periostin, 
and interleukin (IL)-22 showed a tendency to decrease upon dupilumab treatment. In 
addition to simply analyzing a single serological marker, most recent studies have attempted 
to combine previously suggested serum biomarkers in order to predict the clinical response 
to dupilumab. Bakker et al.17 analyzed 25 adults with moderate-to-severe AD. They combined 
TARC, soluble IL-2 receptor, and IL-22 to provide predictive-EASI (p-EASI) which predicts 
the real EASI. This model demonstrated that the p-EASI corresponds well with disease 
severity in AD patients, especially before and after 8–16 weeks of dupilumab treatment. 
Most recent reports conducting mathematical model-based meta-analyses of dupilumab 
clinical trials showed that the baseline level of IL-13 can be used to stratify dupilumab 
responders.18 In this article, they also identified candidate biomarkers to predict the response 
to dupilumab. When the criterion for good or bad responses is set at EASI-75, lower baseline 
blood eosinophil count and baseline LDH level were significantly associated with better 
response to dupilumab.12 Although many studies, including this article, have intended to 
define biomarkers to predict dupilumab response or follow up clinical improvement after 
dupilumab treatment, most of them contains a relatively low number of subjects. Also, the 
retrospective nature of the above studies limits further generalized interpretation in real 
clinical settings.
In the era of new pathophysiology-based therapeutics in AD, understanding of AD is 
becoming better and facing the unprecedented phase. Since the appearance of dupilumab, 
other biologics including tralokinumab and lebrikizumab as well as small molecules such 
as Janus Kinase (JAK) inhibitors (baricitinib, etc.), are emerging in real clinical practice. 
However, it is time to start to fully understand and to re-define the vague concept of AD. In 
the article by Lee et al.,12 even if there are still some limitations, continuous accumulation of 
studies reflecting the actual clinical environment would be able to extend the use of biologics 
such as dupilumab, and also could help us select a proper interval based on the severity 
of AD and control side effects of biologics. Eventually, a new protocol for using biologics 
including dupilumab, will be established, so that biologics and small molecules can replace 
conventional immunosuppressants.
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